{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T19:57:23Z","timestamp":1771531043038,"version":"3.50.1"},"reference-count":39,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"unspecified","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015471","name":"Mater Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015471","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007287","name":"Worldwide Cancer Research","doi-asserted-by":"publisher","award":["15-0181"],"award-info":[{"award-number":["15-0181"]}],"id":[{"id":"10.13039\/501100007287","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1078987"],"award-info":[{"award-number":["1078987"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2021,1,31]]},"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The conventional type 1 dendritic cell subset (cDC1) is indispensable for tumor immune responses and the efficacy of immune checkpoint inhibitor (ICI) therapies in animal models but little is known about the role of the human CD141<jats:sup>+<\/jats:sup> DC cDC1 equivalent in patients with melanoma.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We developed a flow cytometry assay to quantify and characterize human blood DC subsets in healthy donors and patients with stage 3 and stage 4 metastatic melanoma. To examine whether harnessing CD141<jats:sup>+<\/jats:sup> DCs could improve responses to ICIs in human melanoma, we developed a humanized mouse model by engrafting immunodeficient NSG-SGM3 mice with human CD34<jats:sup>+<\/jats:sup> hematopoietic stem cells (HSCs) from umbilical cord blood followed by transplantation of a human melanoma cell line and treatment with anti-programmed cell death protein-1 (anti-PD-1).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Blood CD141<jats:sup>+<\/jats:sup> DC numbers were significantly reduced in patients with stage 4 melanoma compared with healthy controls. Moreover, CD141<jats:sup>+<\/jats:sup> DCs in patients with melanoma were selectively impaired in their ability to upregulate CD83 expression after stimulation with toll-like receptor 3 (TLR3) and TLR7\/8 agonists ex vivo. Although DC numbers did not correlate with responses to anti-PD-1 and\/or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) ICIs, their numbers and capacity to upregulate CD83 declined further during treatment in non-responding patients. Treatment with anti-PD-1 was ineffective at controlling tumor growth in humanized mice but efficacy was enhanced by indirectly expanding and activating DCs in vivo with <jats:italic>fms<\/jats:italic>-like tyrosine kinase-3 ligand (Flt3L) and a TLR3 agonist. Moreover, intratumoral injections of CD141<jats:sup>+<\/jats:sup> DCs resulted in reduced tumor growth when combined with anti-PD-1 treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These data illustrate quantitative and qualitative impairments in circulating CD141<jats:sup>+<\/jats:sup> DCs in patients with advanced melanoma and that increasing CD141<jats:sup>+<\/jats:sup> DC number and function is an attractive strategy to enhance immunogenicity and response rates to ICIs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2020-001963","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T13:06:37Z","timestamp":1616072797000},"page":"e001963","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":45,"title":["Human CD141<sup>+<\/sup> dendritic cells (cDC1) are impaired in patients with advanced melanoma but can be targeted to enhance anti-PD-1 in a humanized mouse model"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct03789097","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Yoke Seng","family":"Lee","sequence":"first","affiliation":[{"name":"Mater Research, The University of Queensland, Woolloongabba, Queensland, Australia"}]},{"given":"Liam J","family":"O'Brien","sequence":"additional","affiliation":[{"name":"Mater Research, The University of Queensland, Woolloongabba, Queensland, Australia"}]},{"given":"Carina M","family":"Walpole","sequence":"additional","affiliation":[{"name":"Mater Research, The University of Queensland, Woolloongabba, Queensland, Australia"}]},{"given":"Frances E","family":"Pearson","sequence":"additional","affiliation":[{"name":"Mater Research, The University of Queensland, Woolloongabba, Queensland, Australia"}]},{"given":"Ingrid M","family":"Leal-Rojas","sequence":"additional","affiliation":[{"name":"Mater Research, The University of Queensland, Woolloongabba, Queensland, Australia"}]},{"given":"Kelly-Anne","family":"Masterman","sequence":"additional","affiliation":[{"name":"Mater Research, The University of Queensland, Woolloongabba, Queensland, Australia"}]},{"given":"Victoria","family":"Atkinson","sequence":"additional","affiliation":[{"name":"Princess Alexandra Hospital Clinical School, The University of Queensland, Woolloongabba, Queensland, Australia"}]},{"given":"Andrew","family":"Barbour","sequence":"additional","affiliation":[{"name":"Princess Alexandra Hospital Clinical School, The University of Queensland, Woolloongabba, Queensland, Australia"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6512-6323","authenticated-orcid":false,"given":"Kristen J","family":"Radford","sequence":"additional","affiliation":[{"name":"Mater Research, The University of Queensland, Woolloongabba, Queensland, Australia"}]}],"member":"239","published-online":{"date-parts":[[2021,3,18]]},"reference":[{"key":"2025100305292928000_9.3.e001963.1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/bs.ircmb.2019.07.006","article-title":"The role of dendritic cells in cancer","volume":"348","author":"Lee","year":"2019","journal-title":"Int Rev Cell Mol Biol"},{"key":"2025100305292928000_9.3.e001963.2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"2025100305292928000_9.3.e001963.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2014.01.005"},{"key":"2025100305292928000_9.3.e001963.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70585-0"},{"key":"2025100305292928000_9.3.e001963.5","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13720","article-title":"The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity","volume":"7","author":"Laoui","year":"2016","journal-title":"Nat Commun"},{"key":"2025100305292928000_9.3.e001963.6","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2016.03.012","article-title":"Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition","volume":"44","author":"Salmon","year":"2016","journal-title":"Immunity"},{"key":"2025100305292928000_9.3.e001963.7","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0510"},{"key":"2025100305292928000_9.3.e001963.8","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.trecan.2018.09.001","article-title":"The role of type 1 conventional dendritic cells in cancer immunity","volume":"4","author":"B\u00f6ttcher","year":"2018","journal-title":"Trends Cancer"},{"key":"2025100305292928000_9.3.e001963.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.09.024"},{"key":"2025100305292928000_9.3.e001963.10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00009","article-title":"Are conventional type 1 dendritic cells critical for protective antitumor immunity and how?","volume":"10","author":"Cancel","year":"2019","journal-title":"Front Immunol"},{"key":"2025100305292928000_9.3.e001963.11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0410-x"},{"key":"2025100305292928000_9.3.e001963.12","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0565-5"},{"key":"2025100305292928000_9.3.e001963.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.02.008"},{"key":"2025100305292928000_9.3.e001963.14","doi-asserted-by":"crossref","unstructured":"Lin JH , Huffman AP , Wattenberg MM , et al . Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis. J Exp Med 2020;217.doi:10.1084\/jem.20190673","DOI":"10.1084\/jem.20190673"},{"key":"2025100305292928000_9.3.e001963.15","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000474"},{"key":"2025100305292928000_9.3.e001963.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.04.003"},{"key":"2025100305292928000_9.3.e001963.17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0085-8"},{"key":"2025100305292928000_9.3.e001963.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.01.004"},{"key":"2025100305292928000_9.3.e001963.19","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-00608-2","article-title":"Predictors of responses to immune checkpoint blockade in advanced melanoma","volume":"8","author":"Jacquelot","year":"2017","journal-title":"Nat Commun"},{"key":"2025100305292928000_9.3.e001963.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2025100305292928000_9.3.e001963.21","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.12097"},{"key":"2025100305292928000_9.3.e001963.22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01419","article-title":"Human CD141+ dendritic cell and CD1c+ dendritic cell undergo concordant early genetic programming after activation in humanized mice in vivo","volume":"8","author":"Minoda","year":"2017","journal-title":"Front Immunol"},{"key":"2025100305292928000_9.3.e001963.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2003.10.006"},{"key":"2025100305292928000_9.3.e001963.24","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1695"},{"key":"2025100305292928000_9.3.e001963.25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00971","article-title":"Human blood CD1c+ dendritic cells promote Th1 and Th17 effector function in memory CD4+ T cells","volume":"8","author":"Leal Rojas","year":"2017","journal-title":"Front Immunol"},{"key":"2025100305292928000_9.3.e001963.26","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/imcb.12009","article-title":"Activation of human CD141(+) and CD1c(+) dendritic cells in vivo with combined TLR3 and TLR7\/8 ligation","volume":"96","author":"Pearson","year":"2018","journal-title":"Immunol Cell Biol"},{"key":"2025100305292928000_9.3.e001963.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2014.09.007"},{"key":"2025100305292928000_9.3.e001963.28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1609376113"},{"key":"2025100305292928000_9.3.e001963.29","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-03600-6","article-title":"Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance","volume":"9","author":"Meyer","year":"2018","journal-title":"Nat Commun"},{"key":"2025100305292928000_9.3.e001963.30","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw016"},{"key":"2025100305292928000_9.3.e001963.31","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/CMR.0000000000000333","article-title":"Basal neutrophil-to-lymphocyte ratio is associated with overall survival in melanoma","volume":"27","author":"Lino-Silva","year":"2017","journal-title":"Melanoma Res"},{"key":"2025100305292928000_9.3.e001963.32","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejca.2020.04.036","article-title":"Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer","volume":"135","author":"Mastelic-Gavillet","year":"2020","journal-title":"Eur J Cancer"},{"key":"2025100305292928000_9.3.e001963.33","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx190"},{"key":"2025100305292928000_9.3.e001963.34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1805"},{"key":"2025100305292928000_9.3.e001963.35","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.celrep.2018.07.033","article-title":"Large-Scale human dendritic cell differentiation revealing Notch-dependent lineage bifurcation and heterogeneity","volume":"24","author":"Balan","year":"2018","journal-title":"Cell Rep"},{"key":"2025100305292928000_9.3.e001963.36","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1016\/j.celrep.2018.05.068","article-title":"Notch Signaling Facilitates In Vitro Generation of Cross-Presenting Classical Dendritic Cells","volume":"23","author":"Kirkling","year":"2018","journal-title":"Cell Rep"},{"key":"2025100305292928000_9.3.e001963.37","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-011-1231-2"},{"key":"2025100305292928000_9.3.e001963.38","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20150642"},{"key":"2025100305292928000_9.3.e001963.39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02303","article-title":"In situ vaccination by direct dendritic cell inoculation: the coming of age of an old idea?","volume":"10","author":"Castiello","year":"2019","journal-title":"Front Immunol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-001963","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:29:39Z","timestamp":1759494579000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-001963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":39,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,18]]},"published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1136\/jitc-2020-001963"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-001963","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3]]}}}